CTC Clinical Trial Consultants AB

Research at CTC Clinical Trial Consultants AB is centered on developing innovative therapies for male urogenital diseases, particularly erectile dysfunction.

• Safety assessment of new biologic agents
• Pharmacokinetic profiling of subcutaneous formulations
• Exploration of combination therapies for urogenital conditions

The study contributes to expanding therapeutic choices for men with erectile dysfunction, aligning with CTC's commitment to advancing urogenital care.

The metabolic program at the site targets overweight and obesity, aiming to evaluate novel anti‑obesity therapy that supports weight management and metabolic health.

• Safety and tolerability of emerging anti‑obesity compounds
• Pharmacodynamic evaluation of metabolic regulators
• Assessment of co‑administration strategies for weight loss

These trials seek to broaden treatment options for individuals struggling with obesity, reinforcing CTC’s focus on metabolic disease research.

In the respiratory division, CTC investigates therapies for idiopathic pulmonary fibrosis, a progressive condition within respiratory tract diseases.

• Safety monitoring of investigational inhaled agents
• Pharmacokinetic studies in pulmonary disease
• Exploration of disease‑modifying potential in fibrotic lungs

The research aims to improve outcomes for patients with fibrotic lung disease, reflecting the site’s dedication to advancing respiratory health.